Innomedica

What Innomedica does

InnoMedica is a privately-held Swiss pharmaceutical company founded in 2000 and headquartered in Zug, with a manufacturing site in Marly, Switzerland. The company is built on a patented drug delivery technology platform and is advancing two proprietary drug candidates: Talidox, for which a regulatory dossier has been submitted, and Talineuren, for which clinical trials have been initiated. In addition to its internal development pipeline, InnoMedica has expanded its commercial scope through a February 2026 exclusive distribution agreement with Nutriband (NTRB) covering AVERSA Fentanyl and sports tape products manufactured at Nutriband's Pocono Pharmaceutical/Active Intell subsidiary, with Innomedica responsible for overseeing and financing regulatory approvals.

The company operates with a very small team (1–10 employees) and is led by founders Stefan Halbherr, Andrea Zurkirchen, and Chairman Herbert Fruh, alongside project management and finance leadership. Its revenue model is not yet commercialized: capital is raised through periodic equity rounds (cumulative funding of approximately CHF 25–30M+ across 2014–2021, including a CHF 15M capital increase in 2021) to fund regulatory submissions and clinical development. InnoMedica's customer base is undisclosed and it is currently pre-revenue on its own products, with the Nutriband arrangement representing its first significant commercial distribution vehicle. Operating geographies span Switzerland (Europe) and Costa Rica (Central America) via the Nutriband partnership.

InnoMedica's strategic posture combines late-stage clinical development of its own pipeline with a distribution-led revenue bridge via third-party products. The combination positions the company to potentially leverage its regulatory expertise across both proprietary and partnered assets, though the absence of disclosed product revenue, the small employee base, and dependence on continued capital raises are material considerations for investors.

Name

Innomedica

Website

https://innomedica.com

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

11–50 employees

Short description

InnoMedica is a Swiss clinical-stage pharmaceutical company developing proprietary drug candidates Talidox and Talineuren on a patented drug delivery platform, and holds exclusive distribution rights to Nutriband's AVERSA Fentanyl and sports tape products.

Ownership category

akta.pro rank

Product category

Pharmaceutical Drug Development

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Nasal Drug Delivery Devices (Sprays/Powder Devices) (HLAHAIAK)

akta.pro secondary industries

Small-Molecule API Process Development & Route Scouting (HLAGAHAA), Specialty Pharmaceutical Distributors (HLAIAJAB)

Keywords

• Pharmaceutical drug delivery
• Drug candidate development
• Clinical trials
• Pharmaceutical manufacturing
• Regulatory submissions

Headquarters

HQ city

Zug

HQ country

Switzerland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Core offering

InnoMedica is a Swiss pharmaceutical company developing proprietary drug delivery technology. Its pipeline includes lead drug candidate Talidox (regulatory dossier submitted) and Talineuren (clinical trials initiated). The company also holds exclusive distribution rights for AVERSA Fentanyl and sports tape products through a partnership with Nutriband, with manufacturing operations in Marly, Switzerland.

Product overview

InnoMedica is a Swiss pharmaceutical company based in Zug with a manufacturing site in Marly. The company's product portfolio includes proprietary drug candidates Talidox (regulatory dossier submitted) and Talineuren (clinical trials initiated), both in its own development pipeline. Additionally, InnoMedica holds exclusive distribution rights for AVERSA Fentanyl and sports tape products through an exclusive distribution agreement with Nutriband.

Differentiator

Problem solved

Functional benefit

Products and services

• Talidox Lead drug candidate of InnoMedica, with a regulatory dossier submitted. The company is developing this pharmaceutical product using its proprietary drug delivery technology.
• Talineuren Drug candidate of InnoMedica for which clinical trials have been initiated, leveraging the company's proprietary drug delivery technology.
• AVERSA Fentanyl Fentanyl-based product for which InnoMedica holds exclusive distribution rights through the Nutriband agreement, contingent on regulatory approval.
• Sports tape products Sports tape products manufactured at the Pocono Pharmaceutical/Active Intell subsidiary, for which InnoMedica has exclusive distribution rights through the Nutriband agreement.

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• NutribandcoreChannel Partner/ Reseller/ Distributor · 17 February 2026Nutriband (NTRB) signed an exclusive distribution agreement with Innomedica covering AVERSA Fentanyl (contingent on regulatory approval) and all sports tape products manufactured at its Pocono Pharmaceutical/Active Intell subsidiary. Under the terms, Innomedica will oversee and finance all regulatory approvals for the products as they prepare for market launch. The agreement grants Innomedica exclusive rights to distribute these products.

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Novartis: Swiss-headquartered global pharmaceutical major with extensive drug delivery and specialty pharma operations. Relevant as a broad incumbent operating in the same Swiss pharma ecosystem in which InnoMedica competes for talent, capital, and partnerships.
• Roche: Swiss-headquartered global pharmaceutical and diagnostics leader. Relevant as a broad incumbent defining the Swiss pharma competitive and partnership environment in which a small drug delivery specialist like InnoMedica operates.

Direct peers

• Vifor Pharma: Swiss specialty pharma focused on iron deficiency, nephrology, and cardio-renal therapies. Comparable as a Switzerland-headquartered, privately-held specialty pharmaceutical company developing differentiated prescription products.
• Camurus: Swedish specialty pharma built around a proprietary drug delivery technology (FluidCrystal) used to develop improved formulations of established molecules. Highly comparable to InnoMedica's model of monetizing a patented delivery platform through proprietary drug candidates.
• Hovione: Portugal-based pharmaceutical contract developer and manufacturer with deep expertise in particle engineering and drug delivery. Comparable to InnoMedica's combination of proprietary formulation know-how and pharmaceutical manufacturing capability.
• Helsinn: Swiss privately-held specialty pharma focused on supportive care and oncology with proprietary formulations. Comparable as a similarly-sized, Switzerland-based specialty pharma developing differentiated drug products.
• Basilea Pharmaceutica: Swiss specialty pharma developing and commercializing innovative drugs for severe infections and oncology. Comparable as a Switzerland-based specialty pharma advancing proprietary clinical-stage candidates.
• Polypeptide Group: Swiss-based manufacturer of peptide and small-molecule APIs and intermediates for pharmaceutical customers. Comparable as a Swiss-headquartered pharma manufacturing company with proprietary process technology and B2B distribution.
• Pacira BioSciences: US specialty pharma commercializing liposomal drug delivery products such as Exparel. Comparable to InnoMedica in using proprietary delivery technology to create differentiated injectable pharmaceutical products.
• Tillotts Pharma: Swiss specialty pharma with a portfolio of gastroenterology products and proprietary drug delivery/ formulation work. Comparable as a Swiss-headquartered specialty pharma focused on differentiated prescription products.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/innomedica
• LinkedInlinkedin.com/company/innomedica-holding-ag

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds6 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Innomedica